TLX revenueFY2025$803.79M
- FY YoY
- +55.6%
TLX revenue was $803.79M for fiscal 2025 (ended Dec 31, 2025), up 55.6% from fiscal 2024.
Telix Pharmaceuticals Limited (TLX) financials
For fiscal 2025 (ended Dec 31, 2025), Telix Pharmaceuticals Limited reported $803.79M of revenue and -$7.13M of net income.
- Revenue, FY2025
- $803.79M
- Revenue growth, YoY
- +55.6%
- Net income, FY2025
- -$7.13M
- Net margin
- -0.9%
- Free cash flow, FY2025
- -$42.98M
- EPS, diluted, FY2025
- -$0.02
- Cash
- $141.87M
- Total debt
- $391.91M
- P/S
- 4.06
- Market cap
- $3.26B
FY2023FY2025
FY2023FY2025
FY2023FY2025
TLX revenue and earnings growth
TLX net incomeFY2025-$7.13M
TLX net income was -$7.13M for fiscal 2025 (ended Dec 31, 2025), compared with $33.69M in fiscal 2024.
TLX EPSFY2025-$0.02
TLX diluted EPS was -$0.02 for fiscal 2025 (ended Dec 31, 2025), compared with $0.10 in fiscal 2024.
TLX free cash flowFY2025-$42.98M
TLX free cash flow was -$42.98M for fiscal 2025 (ended Dec 31, 2025), compared with $18.37M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | $803.79M | $516.55M | $332.98M |
| Cost of revenue | $377.36M | $180.39M | $123.44M |
| Gross profit | $426.44M | $336.16M | $209.53M |
| Research and development | $171.25M | $127.93M | $85.31M |
| Selling, general and admin | $95.79M | $85.32M | $49.67M |
| Operating income | $29.78M | $55.18M | $11.01M |
| Interest expense | $181.0K | $64.0K | $97.0K |
| Pre-tax income | -$5.27M | $37.91M | $2.59M |
| Income tax | $1.86M | $4.23M | -$1.61M |
| Net income | -$7.13M | $33.69M | $4.21M |
| EPS, basic | -$0.02 | $0.10 | $0.01 |
| EPS, diluted | -$0.02 | $0.10 | $0.01 |
| Diluted shares | 337.9M | 345.2M | 323.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $141.87M | $440.00M | $84.30M |
| Receivables | $129.20M | $86.93M | $44.04M |
| Inventory | $37.08M | $23.62M | $12.74M |
| Current assets | $330.28M | $570.12M | $158.69M |
| Goodwill | $198.99M | $66.59M | - |
| Total assets | $1.16B | $940.38M | $277.26M |
| Current liabilities | $231.62M | $205.09M | $111.37M |
| Long-term debt | $391.91M | $341.81M | $5.95M |
| Total debt | $391.91M | $341.81M | $5.95M |
| Total liabilities | $748.61M | $587.44M | $174.61M |
| Shareholders' equity | $415.38M | $352.94M | $102.64M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$17.29M | $27.49M | $14.27M |
| Capital expenditures | $25.69M | $9.12M | $6.31M |
| Free cash flow | -$42.98M | $18.37M | $7.97M |
| Investing cash flow | -$285.92M | -$86.69M | -$16.84M |
| Financing cash flow | -$3.72M | $416.79M | $7.09M |
| Stock-based compensation | $19.35M | $12.93M | $5.85M |
| Depreciation and amortization | $21.41M | $5.28M | $4.16M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue growth, YoY | 55.6% | 55.1% | - |
| Net income growth, YoY | - | 700.5% | - |
| EPS growth, YoY | - | 650.8% | - |
| Gross margin | 53.1% | 65.1% | 62.9% |
| Operating margin | 3.7% | 10.7% | 3.3% |
| Net margin | -0.9% | 6.5% | 1.3% |
| Free cash flow margin | -5.3% | 3.6% | 2.4% |
| Return on equity | -1.7% | 9.5% | 4.1% |
| Return on assets | -0.6% | 3.6% | 1.5% |
| Current ratio | 1.43 | 2.78 | 1.42 |
| Debt to equity | 0.94 | 0.97 | 0.06 |
Source: XBRL data Telix Pharmaceuticals Limited files with the SEC, latest filing dated Feb 20, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
TLX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TLX | $803.79M | +55.6% | -$7.13M | -0.9% | $3.26B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
TLX FAQ
9 questionsWhat is TLX revenue?
Telix Pharmaceuticals Limited (TLX) reported $803.79M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 55.6% from the year before.Is TLX profitable?
No. Telix Pharmaceuticals Limited reported a net loss of $7.13M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does TLX have?
Telix Pharmaceuticals Limited reported $141.87M in cash and cash equivalents and $391.91M of debt on its most recent balance sheet in SEC filings.How fast is TLX revenue growing?
Telix Pharmaceuticals Limited's revenue changed +55.6% in fiscal 2025, to $803.79M.What is TLX gross margin?
Telix Pharmaceuticals Limited's gross profit was $426.44M on $803.79M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 53.1%.What is TLX free cash flow?
Telix Pharmaceuticals Limited generated -$42.98M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$17.29M less capital expenditures.What is TLX earnings per share?
Diluted earnings per share were -$0.02 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did TLX last report financial results?
The latest statements here come from Telix Pharmaceuticals Limited's 20-F filed on Feb 20, 2026, covering the period ended Dec 31, 2025.Where does this TLX financial data come from?
Quantisnow builds these statements from the structured XBRL data Telix Pharmaceuticals Limited files with the SEC. It is provided for information only and is not investment advice.